Comparison of scoring systems evaluating suitability for intensive chemotherapy in adults with acute myeloid leukemia—a Grand Ouest Against Leukemia (GOAL) study

Desprez, Christophe; Riou, Jérémie; Péterlin, Pierre; Marchand, Tony; Couturier, Marie‐Anne; Villate, Alban; Méar, Jean-Baptiste; Chevalier, Patrice; Guillerm, Gaëlle; Gyan, Emmanuel; Schmidt-Tanguy, Aline; Walter, Roland B.; Hunault, Mathilde; Orvain, Corentin

doi:10.1038/s41375-022-01677-z

Cited by 5 publications

(2 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Uma avaliação recorrente nestes trabalhos foi o potencial das variáveis e modelos estatísticos apresentados em conseguir prever o risco em relação ao tratamento com a quimioterapia, mas seu uso ainda necessita de cautela. Ou seja, mesmo nas situações de baixa funcionalidade, idosos com comorbidades, doença em estágio avançado ou mesmo situações adversas, como paciente de terapia intensiva, pode ter grupos de pacientes que se beneficiem de um tratamento quimioterápico com intuito curativo (AZOULAY et al, 2017;DESPREZ et al, 2022;HARB et al, 2009;PALMIERI et al, 2020a) .…”

Section: Discussionunclassified

The role of chemotherapy toxicity scales in decision-making for acute leukemia and lymphoma: a scoping review

Rodrigues,

Linard,

Pinto

et al. 2023

CLIUM

View full text Add to dashboard Cite

Acute leukemias and non-Hodgkin lymphomas together rank 4th among the most common neoplasms. With curative treatment options, even in adverse situations, however, the decision-making process is delicate and statistical models can help. To identify the chemotherapy toxicity scales and their role in decision-making for the treatment of patients with acute lymphomas and leukemias, we conducted a scoping review on the PUBMED, BIREME, COCHRANE, and CAPES journal data platforms. Thirty articles were selected using the PRISMA protocol approach. There is no ideal scale for assessing chemotherapy toxicity, but there are common variables, such as comorbidities, functionality, age, LDH, renal function, and disease staging. Predictive models of treatment toxicity in patients with acute leukemia and lymphoma require more robust and prospective studies that include the validation of these models for better applicability.

show abstract

Section: Discussionunclassified

The role of chemotherapy toxicity scales in decision-making for acute leukemia and lymphoma: a scoping review

Rodrigues,

Linard,

Pinto

et al. 2023

CLIUM

View full text Add to dashboard Cite

show abstract

“…Recent clinical trials testing therapies for those "unfit for intensive treatment" utilize consensus criteria (Ferrara criteria) to define eligibility. These criteria include age (>75 years), major comorbidities, and performance status and have not yet been validated prospectively [13][14][15]. The reliance on age alone as a surrogate for "fitness" remains a limitation.…”

Section: Introductionmentioning

confidence: 99%

Geriatric Assessment in Acute Myeloid Leukemia

Woods,

Klepin

2023

Acta Haematol

View full text Add to dashboard Cite

Background Acute myeloid leukemia (AML) is a heterogenous disease that affects mostly older adults with varying baseline health and functional status. Treatment options have expanded for older adults ranging from less intensive chronic therapies to intensive induction strategies with curative intent. Despite this, outcomes remain poor with advancing age due to underlying disease biology and variability in treatment tolerance. Reliance on chronologic age alone, however, increases risks of both over- and under-treatment. Strategies to better characterize fitness in the context of therapy are needed to optimize decision-making and enhance clinical trial design. Summary Geriatric assessment (GA) is a series of validated tools that evaluate multiple health and functional domains of an older adult including physical function, comorbidities, cognition, nutrition, psychological health, and social support. While studies of GA in AML remain limited, current evidence shows that it is feasible to perform GA among older adults starting therapy for AML. GA measures including those assessing physical function, cognition, and mood are associated with mortality and toxicity in both the intensive and less intensive treatment settings. Key Messages In this review, we discuss the existing evidence to support use of GA in AML and highlight implications for clinical practice and future research.

show abstract

Does the regional use of intensive chemotherapy impact the outcome of adults with AML?

Orvain

2024

bmjonc

View full text Add to dashboard Cite

Comparison of scoring systems evaluating suitability for intensive chemotherapy in adults with acute myeloid leukemia—a Grand Ouest Against Leukemia (GOAL) study

Cited by 5 publications

References 25 publications

The role of chemotherapy toxicity scales in decision-making for acute leukemia and lymphoma: a scoping review

The role of chemotherapy toxicity scales in decision-making for acute leukemia and lymphoma: a scoping review

Geriatric Assessment in Acute Myeloid Leukemia

Does the regional use of intensive chemotherapy impact the outcome of adults with AML?

Contact Info

Product

Resources

About